Semler Scientific (SMLR) Registration Filing summary

Company overview and business model

• Provides technology solutions to improve clinical effectiveness and efficiency for healthcare providers, focusing on chronic disease evaluation and treatment.

• Main product, QuantaFlo, is FDA-cleared for measuring arterial blood flow to aid in diagnosing cardiovascular diseases, with ongoing efforts to expand its indications.

• Recently adopted bitcoin as its primary treasury reserve asset, holding 828 bitcoins as of June 6, 2024, and views bitcoin as a long-term store of value.

• Faces regulatory changes as CMS phases in a new Medicare Advantage risk adjustment model, impacting payments related to peripheral arterial disease.

Financial performance and metrics

• As of March 31, 2024, 6,919,771 shares of common stock were outstanding, with additional options and shares available under equity plans.

• After a $50 million offering at $29.87 per share, as adjusted net tangible book value would be $126.7 million, or $18.37 per share.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for general corporate purposes, including working capital, R&D, capital expenditures, potential acquisitions, and notably, the acquisition of bitcoin.

• Management retains broad discretion over allocation of proceeds.